National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
Dec 1, 2011 - 5:00:00 AM
|
|
We are proud to contribute such a significant body of scientific research, said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center. We are thankful to the patients who entrust us and participate in our clinical trials, the physicians who lead this research at our institution, and the institutions we collaborate with to help us accelerate the development of novel and combination therapies.
By John Theurer Cancer Center,
[RxPG] Hackensack, N.J. (December 1, 2011) - The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.
More than half of the John Theurer Cancer Center presentations showcased at the ASH Annual Meeting have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, multi-center, international trials in collaboration with leading cancer institutions such as the National Cancer Institute, MD Anderson, Dana-Farber, Mayo Clinic, and Memorial Sloan-Kettering.
Personalizing therapies will certainly play a growing role in the practice of oncology, said Andre Goy, M.D., M.S., chairman and director, chief of lymphoma, and director, clinical and translational cancer research. Our center is part of many studies researching novel therapies as well as the identification of biomarkers predictive of outcomes in cancer.
ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The research presented by the John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia.
Seven John Theurer Cancer Center physicians are first or senior authors, including Dr. Goy; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Anthony Mato, M.D., oncologist, lymphoma; Joshua Richter, M.D., oncologist, multiple myeloma; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma; and David Vesole, M.D., Ph.D., co-chief and director of research, multiple myeloma.
John Theurer Cancer Center experts will also participate in panel discussions and moderate sessions. Dr. Siegel will present a complicated case at the International Hematologic Oncology Tumor Board during the Friday Satellite Symposium preceding the ASH Annual Meeting. In addition, Dr. Goy will moderate an oral and poster session featuring lymphoma chemotherapy.
We are proud to contribute such a significant body of scientific research, said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center. We are thankful to the patients who entrust us and participate in our clinical trials, the physicians who lead this research at our institution, and the institutions we collaborate with to help us accelerate the development of novel and combination therapies.
For those attending the ASH annual meeting, visit the John Theurer Cancer Center at Booth 1923. The following are abstracts and presentations at ASH annual meeting from the John Theurer Cancer Center. For ongoing updates, please visit
Related Latest Research News
|
|
Subscribe to Latest Research Newsletter
|
|
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
